Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00961441 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
A Phase 2 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00961441 is a Phase 2 study that has completed, run by UCB Biosciences. The registered enrollment target is 25 participants.
The verdict
NCT00961441, a Phase 2 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.
Interventions
- DRUG Keppra XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00961441
The ClinicalTrials.gov registry entry for NCT00961441 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Keppra XR is the first listed.
NCT00961441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00961441 about?
NCT00961441 is a clinical study titled "Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy". To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.
What is the current status of trial NCT00961441?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2009-09. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00961441?
The interventions under investigation include: Keppra XR (DRUG).
Who is sponsoring clinical trial NCT00961441?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.